Modified short interfering nucleic acid (siNA) molecules and uses thereof

US11549110B2 · kind B2 · utility

Assignee

• Aligos Therapeutics, Inc. · US

Inventors

• Leonid Beigelman · San Mateo, US
• Vivek Kumar Rajwanshi · Cupertino, US
• Markus Hossbach · Kulmbach, DE
• Rajendra K. Pandey · Foster City, US
• Jin Hong · Pacifica, US
• Laxman Eltepu · San Diego, US
• Saul Martinez Montero · San Bruno, US
• N. Tilani S. De Costa · South San Francisco, US

Key dates

• Filing date: Feb 15, 2022
• Grant date: Jan 10, 2023
• Expiry date: Feb 15, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2′-O-methyl nucleotides and 2′-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5′-stabilized end cap; and (b) a short interfering nucleic acid (siNA).